NASDAQ:GILD 22 August 2025 - 20 December 2025

Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81stockanalysis.comstockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47%ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same periodts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects mounting investor enthusiasm driven by a confluence of positive news. “Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects,” TechStock² noted in an analysists2.tech. Notably, this latest upswing builds on momentum from the summer. In August, Gilead’s Q2 earnings beat expectations, and the company raised its full-year outlook, citing surging demand for its core HIV treatments and other drugs. That earnings surprise sent GILD shares up about 7–8% in a single dayts2.technasdaq.com. Since then, the stock has continued climbing to new highs as optimism grows about Gilead’s growth trajectory heading into year-endts2.tech.